JP2020519645A - 脂肪組織由来幹細胞による多発性硬化症の治療 - Google Patents

脂肪組織由来幹細胞による多発性硬化症の治療 Download PDF

Info

Publication number
JP2020519645A
JP2020519645A JP2019562579A JP2019562579A JP2020519645A JP 2020519645 A JP2020519645 A JP 2020519645A JP 2019562579 A JP2019562579 A JP 2019562579A JP 2019562579 A JP2019562579 A JP 2019562579A JP 2020519645 A JP2020519645 A JP 2020519645A
Authority
JP
Japan
Prior art keywords
hadsc
cells
adipose tissue
pellet
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019562579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519645A5 (enExample
Inventor
マロム，エフド
グリンスパン，フリーダ
ユーディン，ディマ
Original Assignee
ステム セル メディスン リミテッド
ステム セル メディスン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステム セル メディスン リミテッド, ステム セル メディスン リミテッド filed Critical ステム セル メディスン リミテッド
Publication of JP2020519645A publication Critical patent/JP2020519645A/ja
Publication of JP2020519645A5 publication Critical patent/JP2020519645A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019562579A 2017-05-15 2018-05-14 脂肪組織由来幹細胞による多発性硬化症の治療 Pending JP2020519645A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506006P 2017-05-15 2017-05-15
US62/506,006 2017-05-15
PCT/IL2018/050523 WO2018211498A1 (en) 2017-05-15 2018-05-14 Treatment of multiple sclerosis with adipose-derived stem cells

Publications (2)

Publication Number Publication Date
JP2020519645A true JP2020519645A (ja) 2020-07-02
JP2020519645A5 JP2020519645A5 (enExample) 2021-05-06

Family

ID=64274150

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019562579A Pending JP2020519645A (ja) 2017-05-15 2018-05-14 脂肪組織由来幹細胞による多発性硬化症の治療

Country Status (8)

Country Link
US (1) US11510946B2 (enExample)
EP (1) EP3624816A4 (enExample)
JP (1) JP2020519645A (enExample)
CN (1) CN110573170A (enExample)
AU (1) AU2018270396B2 (enExample)
CA (1) CA3062123A1 (enExample)
IL (1) IL269893B2 (enExample)
WO (1) WO2018211498A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519658A (ja) * 2017-05-15 2020-07-02 ステム セル メディスン リミテッド 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療
US11510946B2 (en) 2017-05-15 2022-11-29 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272145A (en) 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic preparations with protein concentrate from a conditioned growth medium of stem cells from adipose tissue
CN115624571A (zh) * 2022-12-21 2023-01-20 北京瑷格干细胞科技有限公司 人脂肪间充质干细胞在制备治疗硬皮病药物中的应用
CN115624570A (zh) * 2022-12-21 2023-01-20 北京瑷格干细胞科技有限公司 人脂肪间充质干细胞在制备治疗结缔组织疾病药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015511221A (ja) * 2012-01-31 2015-04-16 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 神経炎症性障害の処置のための第ｘｉｉ因子阻害剤
US20170065638A1 (en) * 2014-02-10 2017-03-09 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
DK1248643T3 (da) 2000-01-20 2005-11-07 Yeda Res & Dev Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
NZ569331A (en) 2003-01-21 2010-08-27 Yeda Res & Dev COP 1 for treatment of inflammatory bowel diseases
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
AU2005308396B2 (en) 2004-11-29 2011-06-09 Yeda Research And Development Co. Ltd. Induction of neurogenesis and stem cell therapy in combination with Copolymer 1
WO2006060779A2 (en) 2004-12-03 2006-06-08 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
JP4654015B2 (ja) 2004-12-08 2011-03-16 京セラ株式会社 カメラ装置
US20070003528A1 (en) 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
NZ597304A (en) 2005-10-13 2013-06-28 Anthrogenesis Corp Immunomodulation using placental stem cells
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2008024996A2 (en) 2006-08-24 2008-02-28 Johnstone Brian H Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
CA2668200C (en) 2006-11-03 2017-04-18 Multiple Sclerosis Research Center Of New York Bone marrow-derived mesenchymal stem cells as a source of neural progenitors
WO2011041240A1 (en) 2009-09-30 2011-04-07 The Brigham And Women's Hospital, Inc. Tissue transplant compositions and methods for use
US8703180B1 (en) 2007-10-23 2014-04-22 Abbott Cardiovascular Systems Inc. Multiple growth factor compositions, methods of fabrication, and methods of treatment
EP2278873B1 (en) * 2008-03-19 2015-05-06 Cryo-Save AG Improved cryopreservation of adipose tissue for the isolation of mesenchymal stem cells
US20090291061A1 (en) 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
DK2285951T3 (en) 2008-05-28 2018-10-22 Univ Ramot TREATMENT OF CNS DISEASES OF CNS DISEASES
WO2010014990A2 (en) 2008-08-01 2010-02-04 The Board Of Trustees Of The University Of Illinois Method of promoting neurogenesis by modulating secretase activities
WO2010028051A2 (en) 2008-09-03 2010-03-11 Florida State University Research Foundation, Inc. Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors
WO2010045645A1 (en) 2008-10-17 2010-04-22 Baxter International Inc. Methods of obtaining cell populations from adipose tissue
JP5515319B2 (ja) 2009-02-23 2014-06-11 富士レビオ株式会社 脂肪細胞への分化誘導培地及び方法
KR101788885B1 (ko) 2009-07-09 2017-10-20 타이제닉스, 에스.에이.유. 세포 요법에 사용하기 위한 방법 및 조성물
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP3536333B1 (en) 2010-01-04 2022-08-03 Mapi Pharma Limited Depot system comprising glatiramer acetate
US20110212158A1 (en) 2010-02-18 2011-09-01 Samson Tom Immunocompatible chorionic membrane products
WO2012143924A1 (en) 2011-04-21 2012-10-26 Mapi Pharma Ltd. Random pentapolymer for treatment of autoimmune diseases
US20130034524A1 (en) 2011-08-03 2013-02-07 Siamak Agha-Mohammadi Non-Enzymatic Method for Harvesting Adipose-Derived Stromal Cells and Adipose-Derived Stem Cells from Fat and Lipo-Aspirate
SG10201606745XA (en) 2011-09-23 2016-10-28 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions
CL2011002642A1 (es) 2011-10-24 2012-04-09 Univ Del Desarrollo Uso de una composicion formada por un glucocorticoide y una tiazolinediona que sirve para inducir la diferenciacion adipogenica en celulas madres.
SG10201607521PA (en) 2012-03-12 2016-10-28 Univ Singapore Generation of brown adipose tissue (bat) from mesenchymal cells
CN104130975B (zh) * 2013-05-03 2018-07-17 上海市东方医院 人源脂肪干细胞来源的神经元样细胞及其制备方法和应用
TWI642781B (zh) 2014-02-06 2018-12-01 仲恩生醫科技股份有限公司 具優異細胞保護及免疫調節之ｑｕａｄｒｉ－正之基質細胞
AU2017218143B2 (en) 2016-02-12 2023-08-03 Cell Care Therapeutics, Inc. Adipose tissue derived mesenchymal stromal cell conditioned media and methods of making and using the same
US12161688B2 (en) 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CA3062123A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015511221A (ja) * 2012-01-31 2015-04-16 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 神経炎症性障害の処置のための第ｘｉｉ因子阻害剤
US20170065638A1 (en) * 2014-02-10 2017-03-09 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
MEDIATORS OF INFLAMMATION, 2016, VOL.2016, ARTICLE ID 5302120, JPN6021011511, ISSN: 0005065879 *
STEM CELLS INTERNATIONAL, 2015, VOL.2015, ARTICLE ID 146421, JPN6022009739, ISSN: 0005065880 *
WORLD J. STEM CELLS, 2014, VOL.6, NO.3, PP.312-321, JPN6022009737, ISSN: 0004727348 *
中山 享之、加藤 栄史: "脂肪組織由来間葉系幹細胞を利用した細胞療法 −現状と展望−", 日本輸血細胞治療学会誌, vol. 59巻（2013）3号, JPN6022046305, 2013, JP, pages 450 - 456, ISSN: 0005065883 *
吉良 潤一: "最新の多発性硬化症治療", 日本内科学会雑誌, vol. 105巻5号, JPN6022046303, 10 May 2016 (2016-05-10), JP, pages 894 - 904, ISSN: 0005065881 *
風間 智彦: "間葉系幹細胞の基礎と臨床", 日大医学雑誌, vol. 75巻2号, JPN6022046304, 1 April 2016 (2016-04-01), JP, pages 61 - 66, ISSN: 0005065882 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519658A (ja) * 2017-05-15 2020-07-02 ステム セル メディスン リミテッド 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療
JP7000458B2 (ja) 2017-05-15 2022-02-10 ステム セル メディスン リミテッド 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療
US11413311B2 (en) 2017-05-15 2022-08-16 Mapi Pharma Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
US11510946B2 (en) 2017-05-15 2022-11-29 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells

Also Published As

Publication number Publication date
WO2018211498A1 (en) 2018-11-22
IL269893B1 (en) 2023-06-01
US11510946B2 (en) 2022-11-29
CA3062123A1 (en) 2018-11-22
US20200188439A1 (en) 2020-06-18
AU2018270396B2 (en) 2025-03-20
AU2018270396A1 (en) 2020-01-02
CN110573170A (zh) 2019-12-13
IL269893A (enExample) 2019-11-28
EP3624816A4 (en) 2021-02-24
IL269893B2 (en) 2023-10-01
EP3624816A1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
JP2020519645A (ja) 脂肪組織由来幹細胞による多発性硬化症の治療
CN103340904B (zh) 治疗骨关节炎的组合物
US20180353548A1 (en) Scalable production of standardized extracellular vesicles, extracellular vesicle preparations and uses thereof
JP2018531979A (ja) 間葉幹細胞由来のエクソソームおよびその使用
US20210169940A1 (en) Methods of treating or preventing neurological diseases
US10293003B2 (en) Multilineage-differentiating stress enduring (MUSE) cells for treatment of chronic kidney disease
US10596199B2 (en) Methods of treating or preventing rheumatic disease
US20170106021A1 (en) Compositions enriched for hox11+ stem cells and methods of preparing the same
JP7000458B2 (ja) 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療
EP2931876B1 (en) Treatment of diseases of endothelial dysfunction and inflammation
JP6250706B2 (ja) 変形性関節症の予防または治療における異系間質血管層細胞および異系間葉前駆細胞の使用
CN114591913A (zh) 永生化猫干细胞或其用途
JP2024509023A (ja) 肝線維化および／または肝硬変の予防および治療における使用のための、脂肪組織由来再生細胞（ＡＤＲＣｓ）を含む医薬組成物
HK40032278A (en) Treating or preventing rheumatic disease
HK1196541A (en) Methods of treating or preventing neurological diseases
HK1196541B (en) Methods of treating or preventing neurological diseases
HK40014520A (en) Treatment of diseases of endothelial dysfunction and inflammation
HK1210209B (en) Treatment of diseases of endothelial dysfunction and inflammation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220615

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230301

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230301

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230323

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230328

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230526